Brad Adams

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Sara A. Hurvitz, Jennifer L. Caswell‐Jin, Katherine McNamara et al. · Nature Communications · 2020 · 66 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

Edward B. Garon, Jill M. Siegfried, Laura P. Stabile et al. · Lung Cancer · 2018 · 43 citations

Medicine, Oncology, Pharmacotherapy +11

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

Sara A. Hurvitz, Rashi Singh, Brad Adams et al. · Therapeutic Advances in Medical Oncology · 2018 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17

Early life history transitions and recruitment of Picea mariana in thawed boreal permafrost peatlands

Philip Camill, Laura M. Chihara, Brad Adams et al. · Ecology · 2010 · 26 citations

Life Sciences, Ecology, Plant Biology +13

Abstract S1-02: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07)

SA Hurvitz, JM Miller, Robert Dichmann et al. · Cancer Research · 2013 · 25 citations

Medicine, Oncology, Pharmacology +17